Showing results (211-220 of 443) with videos related to
Sort By:
Pageof 45
Methods in Molecular Biology (Clifton, N.J.)|February 14, 2022
Development of Glypican-2 Targeting Single-Domain Antibody CAR T Cells for NeuroblastomaNan Li, Mitchell HoHepatology Research : the Official Journal of the Japan Society of Hepatology|November 14, 2012
Role of sorafenib in the treatment of advanced hepatocellular carcinoma: An updateAngela Gauthier, Mitchell HoAntibody Therapeutics|April 29, 2021
Emerging antibody-based therapeutics against SARS-CoV-2 during the global pandemicYaping Sun, Mitchell HoAnticancer Research|December 11, 2012
Loss of mesothelin expression by mesothelioma cells grown in vitro determines sensitivity to anti-mesothelin immunotoxin SS1PJingli Zhang, Shuo Qiu, Yujian Zhang, et al.Molecular Cancer Therapeutics|November 9, 2012
A recombinant immunotoxin against the tumor-associated antigen mesothelin reengineered for high activity, low off-target toxicity, and reduced antigenicityJohn E Weldon, Laiman Xiang, Jingli Zhang, et al.Proceedings of the National Academy of Sciences of the United States of America|February 26, 2015
Whole-genome RNAi screen highlights components of the endoplasmic reticulum/Golgi as a source of resistance to immunotoxin-mediated cytotoxicityMatteo Pasetto, Antonella Antignani, Pinar Ormanoglu, et al.International Journal of Cancer|September 9, 2010
Affinity-matured anti-glycoprotein NMB recombinant immunotoxins targeting malignant gliomas and melanomasChien-Tsun Kuan, Kenji Wakiya, Stephen T Keir, et al.Cancer Research|January 1, 2016
Anticancer Effects of Mesothelin-Targeted Immunotoxin Therapy Are Regulated by Tyrosine Kinase DDR1Fatima Ali-Rahmani, David J FitzGerald, Scott Martin, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 14, 2002
Antitumor activity of SS(dsFv)PE38 and SS1(dsFv)PE38, recombinant antimesothelin immunotoxins against human gynecologic cancers grown in organotypic culture in vitroRaffit Hassan, Megan R Lerner, Doris Benbrook, et al.Blood|October 4, 2003
Induction of caspase-dependent programmed cell death in B-cell chronic lymphocytic leukemia by anti-CD22 immunotoxinsThomas Decker, Madlene Oelsner, Robert J Kreitman, et al.Pageof 45